Andrew Roddam

EveryONE Medicines is committed to developing individualized precision medicines targeting genetic variants causing fatal, neurodegenerative diseases unique to just a few or even ONE patient. Momentum is building as technological advances with genomic testing and the prevalence of testing is improving rapidly to identify the rarest of rare mutations. Through a collaborative effort across all stakeholders in the treatment and diagnosis of rare genetic disease, EveryONE Medicines will bring a scalable solution to meet the needs of the individual patient who currently has limited hope.